Global Leading Market Research Publisher QYResearch announces the release of its latest report “Plant-based Biologic – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Plant-based Biologic market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Plant-based Biologic was estimated to be worth US$ 60.27 million in 2025 and is projected to reach US$ 105 million, growing at a CAGR of 8.3% from 2026 to 2032.
In 2024, global Plant-based Biologic production reached approximately 3,322, k units, with an average global market price of around US$ 17.26 per unit. Plant-based biologics utilize plants (such as tobacco and corn) as bioreactors, producing biomacromolecules through genetic engineering or transient expression techniques. These include vaccines (such as the COVID-19 VLP vaccine), therapeutic proteins (such as the Gaucher disease drug Elelyso®), and antibodies (such as the Ebola antibody ZMapp). Their key advantages are low cost (no mammalian cell culture required), rapid production (transient expression within 1-2 weeks), and a lack of a cold chain (some are oral or heat-resistant).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095593/plant-based-biologic
1. Strategic Imperative: Disrupting Biologics Manufacturing
Traditional biologics (therapeutic proteins, monoclonal antibodies, vaccines) are produced in mammalian cell culture (CHO, HEK293) at high cost (US$ 100-500 per gram), requiring expensive bioreactors (US$ 500 million+ facilities), cold chain distribution, and lengthy development timelines (12-18 months). Plant-based biologics address these with molecular farming—using plant bioreactors (tobacco, corn, rice, alfalfa) to produce therapeutic proteins, vaccines, and antibodies at significantly lower cost (US$ 10-50 per gram). For biopharmaceutical companies, plant-based platforms offer rapid production (4-8 weeks), scalability (greenhouses vs. stainless steel), and room-temperature stability (no cold chain).
2. Market Trajectory: From Niche to Mainstream Biomanufacturing
According to QYResearch, the global plant-based biologic market was valued at US$ 60.27 million in 2025 and is projected to reach US$ 105 million by 2032, growing at a CAGR of 8.3%. In 2024, production reached approximately 3.32 million units at an average price of US$ 17.26 per unit. Three structural drivers underpin growth:
First, approved commercial products: Elelyso® (Protalix, taliglucerase alfa) for Gaucher disease was the first FDA-approved plant-based therapeutic protein (2012). ZMapp (Kentucky BioProcessing) for Ebola demonstrated efficacy during the 2014-2016 outbreak. Medicago’s COVID-19 VLP vaccine (2025 approval) validates the platform for human vaccines. Second, cost advantage: Plant-based production is 5-10x cheaper than CHO cells (no expensive media, serum, or bioreactors). Third, speed: Transient expression produces clinical-grade material in 4-8 weeks (vs. 6-9 months for stable cell lines), enabling rapid pandemic response.
3. Recent Industry Developments (October 2025 – March 2026)
Four notable trends have reshaped the competitive landscape:
- Elelyso® market expansion: Protalix BioTherapeutics (Israel) expanded Elelyso® (plant-based glucocerebrosidase) into Latin America and Asia, capturing 30% of the Gaucher disease market (US$ 100 million annually). Production cost: US$ 20 per gram vs. US$ 500 for CHO-derived Cerezyme®.
- ZMapp stockpile: The US government maintained a US$ 50 million ZMapp (Ebola antibody) stockpile for biodefense, produced in tobacco plants (Kentucky BioProcessing). Production scale: 1,000 doses/month, yield 50 mg antibody/kg leaf biomass.
- COVID-19 VLP vaccine approval: Medicago’s plant-based COVID-19 VLP vaccine (CoVLP) received Canadian and UK approval (2025). Production scale: 40 million doses/year from a 200,000 sq ft greenhouse. Cost per dose: US$ 5 (vs. US$ 20 for mRNA).
- Non-GMO platform adoption: Baiya Phytopharm (Thailand) and Nomad Bioscience (Germany) developed non-GMO transient expression systems (agroinfiltration without stable transgenics), addressing GMO regulatory concerns in Europe and Japan. Non-GMO segment grew 30% in 2025.
4. Competitive Landscape: Plant-Based Biologic Pioneers
Therapeutic Protein Leaders: Protalix BioTherapeutics (Israel – Elelyso®, PRX-102 for Fabry disease), Eleva (Germany – rice-based Gaucher and Fabry proteins), Moolec Science (UK – molecular farming for food and pharma).
Vaccine Leaders: Medicago (Canada – COVID-19 VLP, influenza, norovirus), IBIO (US – pandemic influenza), Leaf Expression Systems (UK – influenza, veterinary), Baiya Phytopharm (Thailand – COVID-19), CIGB (Cuba – hepatitis B).
Antibody Leaders: Kentucky BioProcessing (US – ZMapp Ebola), Fraunhofer CMB (US – anti-HIV antibodies), PlantForm Corporation (Canada – anti-cancer antibodies).
Platform Specialists: Nomad Bioscience (Germany – non-GMO transient), BioApp (Spain – plant-based adjuvant), Aramis Biotechnologies (France), Icon Genetics (Germany).
Competition centers on three axes: host plant (tobacco for rapid expression, corn/rice for stable storage), expression system (stable transgenic vs. transient), and downstream processing yield (mg antigen/kg biomass).
5. Technology Deep Dive: Plant-Based Biologic Platforms
| Parameter | Stable Transgenic | Transient Agroinfiltration | Mammalian CHO |
|---|---|---|---|
| Time to product | 12-24 months | 4-8 weeks | 9-18 months |
| Yield (mg protein/kg biomass) | 10-100 | 100-1,000 | N/A (g/L bioreactor) |
| Production cost (per gram) | US$ 10-50 | US$ 20-100 | US$ 100-500 |
| Scalability | Field cultivation (acres) | Greenhouse (vertical farming) | Bioreactors (10,000 L) |
| Cold chain requirement | Room temperature (months) | Room temperature (months) | Refrigerated/frozen |
| Regulatory status | GMO concerns (Europe, Japan) | Non-GMO (transient) | Established |
| Example product | Elelyso® (Protalix) | Medicago COVID-19 vaccine | Herceptin® (Genentech) |
Technical challenge: Regulatory acceptance of plant-based biologics (GMO concerns, plant-specific glycosylation). Solutions include:
- Transient expression (no stable transgene integration, non-GMO)
- Glycan engineering (knockout plant-specific fucose/xylose)
- Contained greenhouse production (prevent environmental release)
- Regulatory precedent (Elelyso®, ZMapp, Medicago COVID-19 vaccine)
User Case – Elelyso® (Gaucher Disease) : Protalix’s Elelyso® (taliglucerase alfa) is produced in carrot cell culture (plant-based). Compared to CHO-derived Cerezyme® (US$ 500 per gram), Elelyso® costs US$ 20 per gram (95% reduction). Annual treatment cost for Gaucher disease: US$ 200,000 (Cerezyme®) vs. US$ 40,000 (Elelyso®). Elelyso® captured 30% market share (US$ 100 million annually).
6. Application Segmentation: Therapeutic Proteins, Vaccines, Antibodies
Therapeutic Proteins (≈50% of market, 8% CAGR):
- Enzyme replacement: Gaucher (Elelyso®), Fabry (PRX-102), Pompe (investigational)
- Growth factors: EGF, FGF, VEGF
- Blood factors: Factor VIII, Factor IX (hemophilia)
Vaccines (≈35% of market, 9% CAGR):
- Infectious disease: COVID-19 (Medicago), influenza (seasonal, pandemic), norovirus, Ebola
- Veterinary: Newcastle disease, porcine circovirus
- Cancer: Personalized neoantigen vaccines (early stage)
Antibodies (≈15% of market, 8% CAGR):
- Infectious disease: Ebola (ZMapp), HIV (2G12), influenza
- Oncology: Anti-HER2, anti-PD-1 (investigational)
- Autoimmune: Anti-TNF (investigational)
User Case – ZMapp (Ebola Antibody) : ZMapp (three monoclonal antibodies) produced in tobacco plants (Kentucky BioProcessing). Yield: 50 mg antibody/kg leaf biomass. Production time: 4 weeks from infiltration to purified antibody (vs. 6 months for CHO). During 2014-2016 Ebola outbreak, ZMapp demonstrated 75% efficacy in clinical trial. US government stockpiled ZMapp for biodefense (US$ 50 million contract).
7. Regional Market Dynamics
- North America (50% market share, 9% CAGR): US (IBIO, Kentucky BioProcessing, Fraunhofer CMB, Medicago Canada). Strong government funding (BARDA, CEPI), regulatory approvals (Elelyso®, ZMapp, Medicago COVID-19).
- Europe (25% share, 8% CAGR): Germany (Nomad Bioscience, Icon Genetics, Eleva), UK (Leaf Expression Systems), Spain (BioApp), France (Aramis Biotechnologies). Strong research base, GMO regulatory hurdles slowing commercial products.
- Asia-Pacific (15% share, 9% CAGR): Thailand (Baiya Phytopharm), China, India, Japan, Australia (Moolec Science). Veterinary biologics adoption, emerging human biologics.
- Rest of World (10% share): Israel (Protalix), Cuba (CIGB), Latin America.
8. Strategic Implications for Stakeholders
For biopharmaceutical companies, plant-based platforms offer rapid development (weeks vs. months), low capital investment (greenhouses vs. BSL-3 bioreactors), and cost advantage (5-10x cheaper than CHO). For public health agencies (WHO, CEPI, BARDA), diversifying manufacturing capacity with plant-based biologics reduces reliance on mammalian cell culture. For regulators, establishing clear guidelines for plant-based biologic approval (following Elelyso® and Medicago precedent) will accelerate market entry.
9. Conclusion
The plant-based biologic market is positioned for strong growth through 2032, driven by Elelyso® and Medicago vaccine approvals, cost advantages, and rapid production timelines. Stakeholders should prioritize transient expression platforms (non-GMO, rapid scale-up), thermostable formulations (room temperature distribution), and regulatory approval pathways (FDA, EMA). As biopharmaceutical manufacturing diversifies, plant bioreactors offer a scalable, low-cost, and rapid molecular farming solution for therapeutic proteins, vaccines, and antibodies.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
